KR101278459B1 - Ｇａｇ 결합 단백질 - Google Patents

Ｇａｇ 결합 단백질 Download PDF

Info

Publication number
KR101278459B1
KR101278459B1 KR1020127011106A KR20127011106A KR101278459B1 KR 101278459 B1 KR101278459 B1 KR 101278459B1 KR 1020127011106 A KR1020127011106 A KR 1020127011106A KR 20127011106 A KR20127011106 A KR 20127011106A KR 101278459 B1 KR101278459 B1 KR 101278459B1
Authority
KR
South Korea
Prior art keywords
chemokine
gag binding
protein
gag
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127011106A
Other languages
English (en)
Korean (ko)
Other versions
KR20120063542A (ko
Inventor
안드레아스 제이. 쿤글
Original Assignee
프로타핀 바이오테크놀로기 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로타핀 바이오테크놀로기 아게 filed Critical 프로타핀 바이오테크놀로기 아게
Publication of KR20120063542A publication Critical patent/KR20120063542A/ko
Application granted granted Critical
Publication of KR101278459B1 publication Critical patent/KR101278459B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020127011106A 2003-12-04 2004-12-02 Ｇａｇ 결합 단백질 Expired - Fee Related KR101278459B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0195203A AT412785B (de) 2003-12-04 2003-12-04 Gag-bindungsproteine
ATA1952/2003 2003-12-04
PCT/EP2004/013670 WO2005054285A1 (en) 2003-12-04 2004-12-02 Gag binding proteins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067013411A Division KR101188785B1 (ko) 2003-12-04 2004-12-02 Ｇａｇ 결합 단백질

Publications (2)

Publication Number Publication Date
KR20120063542A KR20120063542A (ko) 2012-06-15
KR101278459B1 true KR101278459B1 (ko) 2013-07-01

Family

ID=33494536

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127011106A Expired - Fee Related KR101278459B1 (ko) 2003-12-04 2004-12-02 Ｇａｇ 결합 단백질
KR1020067013411A Expired - Fee Related KR101188785B1 (ko) 2003-12-04 2004-12-02 Ｇａｇ 결합 단백질

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067013411A Expired - Fee Related KR101188785B1 (ko) 2003-12-04 2004-12-02 Ｇａｇ 결합 단백질

Country Status (20)

Country Link
US (4) US7585937B2 (enExample)
EP (5) EP2363411A1 (enExample)
JP (3) JP4980721B2 (enExample)
KR (2) KR101278459B1 (enExample)
CN (1) CN1890264B (enExample)
AT (3) AT412785B (enExample)
AU (1) AU2004295104B2 (enExample)
BR (1) BRPI0416544A (enExample)
CA (1) CA2546789A1 (enExample)
CY (2) CY1109480T1 (enExample)
DE (1) DE602004022595D1 (enExample)
DK (2) DK1752470T3 (enExample)
ES (2) ES2330362T3 (enExample)
IL (1) IL175565A0 (enExample)
NZ (1) NZ547612A (enExample)
PL (2) PL1752470T3 (enExample)
PT (2) PT1689775E (enExample)
SG (1) SG149000A1 (enExample)
SI (2) SI1689775T1 (enExample)
WO (1) WO2005054285A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
CN100366637C (zh) * 2005-11-17 2008-02-06 中国人民解放军第四军医大学 人白细胞介素8拮抗蛋白及其制备方法
US9422356B2 (en) * 2006-01-31 2016-08-23 Republic Of Korea (Republic Of National Fisheries Research And Development Institute) Artificial signal peptide for expressing an insoluble protein as a soluble active form
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
EP1894571A1 (en) * 2006-08-29 2008-03-05 Protaffin Biotechnologie AG Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection
WO2008140500A2 (en) * 2006-12-08 2008-11-20 The University Of Miami Hyaluronidase inhibitors as anti-cancer agents
AT504685B1 (de) * 2006-12-20 2009-01-15 Protaffin Biotechnologie Ag Fusionsproteine
MX2009012085A (es) * 2007-05-07 2010-01-20 Peptimmune Inc Métodos para la expansión dirigida de epítopes para el uso como ligandos de anticuerpos.
EP2042516A1 (en) * 2007-09-27 2009-04-01 Protaffin Biotechnologie AG Glycosaminoglycan-antagonising MCP-1 mutants and methods of using same
CN101802211B (zh) * 2007-08-02 2014-10-01 诺维莫尼公司 抗正常t细胞表达和分泌活化调节因子(rantes)抗体及其使用方法
EP2053060A1 (en) 2007-10-24 2009-04-29 Protaffin Biotechnologie AG SDF-1-based glyocosaminoglycan antagonists and methods of using same
US8314212B2 (en) * 2008-02-08 2012-11-20 Lindsey Miles Plasminogen receptor PLG-RKT and antibodies thereof
EA201101131A1 (ru) * 2009-01-30 2012-01-30 Протаффин Биотехнологие Аг Новые мутанты мср-1, антагонизирующие гликозаминогликаны, и способы их применения
US20120288474A1 (en) 2009-11-06 2012-11-15 Protaffin Biotechnologie Ag Composition for treatment of cxcl8-mediated lung inflammation
RU2627163C2 (ru) 2009-11-24 2017-08-03 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
EP2686344A1 (en) 2011-03-16 2014-01-22 Protaffin Biotechnologie AG Fgfr1-based antagonists with improved glycosaminoglycan affinity and methods of using same
EP2729487A2 (en) 2011-07-08 2014-05-14 Protaffin Biotechnologie AG Novel sdf-1-based glycosaminoglycan antagonist and methods of using same
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
MX2015000863A (es) 2012-07-19 2016-05-05 Alethia Biotherapeutics Inc Anticuerpos anti-siglec-15.
WO2014079957A1 (de) * 2012-11-23 2014-05-30 Bayer Cropscience Ag Selektive inhibition der ethylensignaltransduktion
KR101457371B1 (ko) * 2013-01-10 2014-11-04 강원대학교산학협력단 작은안구증-연관 전사인자 유래의 펩타이드 및 이를 포함하는 조성물
US10047133B2 (en) 2014-01-22 2018-08-14 Antagonis Biotherapeutics Gmbh Glycosaminoglycan-antagonising fusion proteins and methods of using same
EP4021927A1 (en) 2019-08-29 2022-07-06 Antagonis Biotherapeutics GmbH T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity
CN110791523B (zh) * 2019-12-13 2022-05-10 南京农业大学 一种棉花抗旱相关基因GhRCHY1及其应用
KR20250040765A (ko) * 2023-09-15 2025-03-25 (주)케어젠 펩타이드를 유효성분으로 하는 발모 촉진 또는 탈모증의 억제, 예방 또는 개선용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007935A1 (en) 1990-11-01 1992-05-14 The Scripps Research Institute Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
WO1996034965A2 (en) * 1995-05-05 1996-11-07 Chiron Corporation Chimeric mcp and daf proteins with cell surface localizing domain

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960691A (en) * 1986-09-29 1990-10-02 Abbott Laboratories Chromatographic test strip for determining ligands or receptors
US5234911A (en) * 1990-07-09 1993-08-10 Gist-Brocades, N.V. Substance with interleukin-8 inhibiting activity and process for its preparation
EP0607777B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 8
JP2694321B2 (ja) * 1993-03-10 1997-12-24 大塚製薬株式会社 インターロイキン−１阻害剤
US5527546A (en) * 1994-08-10 1996-06-18 Bayer Corporation Human interleukin 6 inhibitor
JPH1045602A (ja) * 1996-07-31 1998-02-17 Motoyasu Murakami ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−８産生阻害剤
US6852696B2 (en) * 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
EP1581615B1 (en) * 2000-09-05 2010-04-28 Biosight Ltd Peptide conjugated anti-cancer prodrugs
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
JP2003063980A (ja) * 2001-08-28 2003-03-05 Noevir Co Ltd Ｒａｎｔｅｓ産生阻害剤
US6982170B1 (en) * 2001-12-17 2006-01-03 Maine Medical Center Research Institute Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1
JP2003306438A (ja) * 2002-02-18 2003-10-28 Shiseido Co Ltd ケモカイン発現阻害剤
JP2003267887A (ja) * 2002-03-15 2003-09-25 Shiseido Co Ltd ケモカイン発現抑制皮膚外用剤
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
RS89104A (sr) * 2002-04-10 2006-12-15 Applied Research Systems Ars Holding N.V. Novi antagonisti mcp proteina
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007935A1 (en) 1990-11-01 1992-05-14 The Scripps Research Institute Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
WO1996034965A2 (en) * 1995-05-05 1996-11-07 Chiron Corporation Chimeric mcp and daf proteins with cell surface localizing domain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FEBS LETTERS Vol.409(2):183-187 *

Also Published As

Publication number Publication date
SG149000A1 (en) 2009-01-29
NZ547612A (en) 2009-07-31
EP1752470B1 (en) 2009-08-12
US20100331237A1 (en) 2010-12-30
US7585937B2 (en) 2009-09-08
CA2546789A1 (en) 2005-06-16
EP2270038A3 (en) 2011-02-23
CN1890264A (zh) 2007-01-03
CY1109480T1 (el) 2014-08-13
EP1752470A1 (en) 2007-02-14
WO2005054285A1 (en) 2005-06-16
KR101188785B1 (ko) 2012-10-16
ES2330362T3 (es) 2009-12-09
BRPI0416544A (pt) 2007-01-09
US7807413B2 (en) 2010-10-05
DK1752470T3 (da) 2009-12-14
ATE515269T1 (de) 2011-07-15
CY1112330T1 (el) 2015-12-09
EP2311866A1 (en) 2011-04-20
JP2007536906A (ja) 2007-12-20
US20090005541A1 (en) 2009-01-01
JP2012139226A (ja) 2012-07-26
PT1689775E (pt) 2011-10-13
US20080112926A1 (en) 2008-05-15
KR20120063542A (ko) 2012-06-15
EP1689775A1 (en) 2006-08-16
JP2012165747A (ja) 2012-09-06
IL175565A0 (en) 2006-09-05
PL1752470T3 (pl) 2010-01-29
AT412785B (de) 2005-07-25
DE602004022595D1 (de) 2009-09-24
AU2004295104A1 (en) 2005-06-16
SI1689775T1 (sl) 2011-11-30
EP2270038A2 (en) 2011-01-05
ATE439376T1 (de) 2009-08-15
EP1689775B1 (en) 2011-07-06
PT1752470E (pt) 2009-10-15
SI1752470T1 (sl) 2009-12-31
CN1890264B (zh) 2014-01-22
EP2363411A1 (en) 2011-09-07
ES2369139T3 (es) 2011-11-25
JP4980721B2 (ja) 2012-07-18
KR20070001917A (ko) 2007-01-04
AU2004295104B2 (en) 2010-07-22
DK1689775T3 (da) 2011-09-26
ATA19522003A (de) 2004-12-15
PL1689775T3 (pl) 2011-12-30
US20110144305A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
KR101278459B1 (ko) Ｇａｇ 결합 단백질
EP2042516A1 (en) Glycosaminoglycan-antagonising MCP-1 mutants and methods of using same
KR20070008510A (ko) 케모킨 변이체의 치료적 용도
PL204231B1 (pl) Zastosowanie mutanta chemokiny CC, kompozycja farmaceutyczna do leczenia stwardnienia rozsianego, skrócona i zmutowana ludzka RANTES i sposób jej wytwarzania, cząsteczka DNA i zawierający ją wektor ekspresyjny oraz komórka gospodarza
EP2053060A1 (en) SDF-1-based glyocosaminoglycan antagonists and methods of using same
US7365171B2 (en) Chemokine-like factors (CKLFs) with chemotactic and hematopoietic stimulating activities
Wain et al. Rapid site-directed mutagenesis of chemokines and their purification from a bacterial expression system

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20160620

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160620

St.27 status event code: N-4-6-H10-H13-oth-PC1903